|
1
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025.PubMed/NCBI
|
|
2
|
Xiong X, Zheng LW, Ding Y, Chen YF, Cai
YW, Wang LP, Huang L, Liu CC, Shao ZM and Yu KD: Breast cancer:
Pathogenesis and treatments. Signal Transduct Target Ther.
10:492025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guiu S, Michiels S, André F, Cortes J,
Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N,
et al: Molecular subclasses of breast cancer: How do we define
them? The IMPAKT 2012 working group statement. Ann Oncol.
23:2997–3006. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dai X, Xiang L, Li T and Bai Z: Cancer
hallmarks, biomarkers and breast cancer molecular subtypes. J
Cancer. 7:1281–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fedele P, Sanna V, Santoro AN, Iaia ML and
Fancellu A: Tailoring antiHer2 treatment strategies in breast
cancer and beyond. Curr Probl Cancer. 46:1008922022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yin L, Duan JJ, Bian XW and Yu SC:
Triple-negative breast cancer molecular subtyping and treatment
progress. Breast Cancer Res. 22:612020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roskoski R Jr: Targeted and cytotoxic
inhibitors used in the treatment of breast cancer. Pharmacol Res.
210:1075342024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khan A, Sisodiya S, Aftab M, Tanwar P,
Hussain S and Gupta V: Mechanisms and therapeutic strategies for
endocrine resistance in breast cancer: A comprehensive review and
meta-analysis. Cancers (Basel). 17:16532025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoy SM: Elacestrant: First approval.
Drugs. 83:555–561. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ziyeh S, Wong L and Basho RK: Advances in
endocrine therapy for hormone receptor-positive advanced breast
cancer. Curr Oncol Rep. 25:689–698. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stanowicka-Grada M and Senkus E: Anti-HER2
drugs for the treatment of advanced HER2 positive breast cancer.
Curr Treat Options Oncol. 24:1633–1650. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Randall M, Akers R and Rao R: A review of
current and future antibody drug conjugates in breast cancer. Curr
Treat Options Oncol. 25:1506–1516. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhise K, Gavande NS and Iyer AK:
Leveraging hypoxia in triple-negative breast cancer as a promising
treatment strategy. Drug Discov Today. 28:1037612023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Y, Liu CF and Rao GW: A review on poly
(ADP-ribose) polymerase (PARP) inhibitors and synthetic
methodologies. Curr Med Chem. 28:1565–1584. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu S, Ge A, Deng X, Liu L and Wang Y:
Evolving immunotherapeutic solutions for triple-negative breast
carcinoma. Cancer Treat Rev. 130:1028172024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Muriithi W, Macharia LW, Heming CP,
Echevarria JL, Nyachieo A, Filho PN and Neto VM: ABC transporters
and the hallmarks of cancer: Roles in cancer aggressiveness beyond
multidrug resistance. Cancer Biol Med. 17:253–269. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stefan K, Schmitt SM and Wiese M:
9-Deazapurines as broad-spectrum inhibitors of the ABC transport
proteins P-glycoprotein, multidrug resistance-associated protein 1,
and breast cancer resistance protein. J Med Chem. 60:8758–8780.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanssen KM, Wheatley MS, Yu DMT, Conseil
G, Norris MD, Haber M, Cole SPC and Fletcher JI: GSH facilitates
the binding and inhibitory activity of novel multidrug resistance
protein 1 (MRP1) modulators. FEBS J. 289:3854–3875. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nasr R, Lorendeau D, Khonkarn R, Dury L,
Pérès B, Boumendjel A, Cortay JC, Falson P, Chaptal V and
Baubichon-Cortay H: Molecular analysis of the massive GSH transport
mechanism mediated by the human multidrug resistant protein
1/ABCC1. Sci Rep. 10:76162020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Anish Ruban S, Raj FJ and Thangaraj P:
Phytochemical intervention in BCRP-driven cancer drug resistance: A
comprehensive review. Biochim Biophys Acta Rev Cancer.
1880:1893492025. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong J, Yuan L, Hu C, Cheng X and Qin JJ:
Strategies to overcome cancer multidrug resistance (MDR) through
targeting P-glycoprotein (ABCB1): An updated review. Pharmacol
Ther. 249:1084882023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mohammad IS, He W and Yin L: Understanding
of human ATP binding cassette superfamily and novel multidrug
resistance modulators to overcome MDR. Biomed Pharmacother.
100:335–348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alves CL and Ditzel HJ: Drugging the
PI3K/AKT/mTOR pathway in ER+ breast cancer. Int J Mol Sci.
24:45222023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shah D, Ajazuddi n and Bhattacharya S:
Role of natural P-gp inhibitor in the effective delivery for
chemotherapeutic agents. J Cancer Res Clin Oncol. 149:367–391.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu S, Sun C, Cai Z, Li Y, Liu W, Luan Y
and Wang C: Effective therapy of advanced breast cancer through
synergistic anticancer by paclitaxel and P-glycoprotein inhibitor.
Mater Today Bio. 26:1010292024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
de Heer EC, Jalving M and Harris AL: HIFs,
angiogenesis, and metabolism: Elusive enemies in breast cancer. J
Clin Invest. 130:5074–5087. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi S, Ou X, Liu C, Wen H and Ke J:
Research progress of HIF-1a on immunotherapy outcomes in immune
vascular microenvironment. Front Immunol. 16:15492762025.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Francesco EM, Maggiolini M and Musti
AM: Crosstalk between Notch, HIF-1α and GPER in breast cancer EMT.
Int J Mol Sci. 19:20112018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang G, Tao X, Ji B and Gong J:
Hypoxia-driven M2-polarized macrophages facilitate cancer
aggressiveness and temozolomide resistance in glioblastoma. Oxid
Med Cell Longev. 2022:16143362022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Capatina AL, Malcolm JR, Stenning J, Moore
RL, Bridge KS, Brackenbury WJ and Holding AN: Hypoxia-induced
epigenetic regulation of breast cancer progression and the tumour
microenvironment. Front Cell Dev Biol. 12:14216292024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rashid M, Zadeh LR, Baradaran B, Molavi O,
Ghesmati Z, Sabzichi M and Ramezani F: Up-down regulation of HIF-1α
in cancer progression. Gene. 798:1457962021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dominguez-Cejudo MA, Gil-Torralvo A,
Cejuela M, Molina-Pinelo S and Salvador Bofill J: Targeting the
tumor microenvironment in breast cancer: Prognostic and predictive
significance and therapeutic opportunities. Int J Mol Sci.
24:167712023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Akinsipe T, Mohamedelhassan R, Akinpelu A,
Pondugula SR, Mistriotis P, Avila LA and Suryawanshi A: Cellular
interactions in tumor microenvironment during breast cancer
progression: New frontiers and implications for novel therapeutics.
Front Immunol. 15:13025872024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kundu M, Butti R, Panda VK, Malhotra D,
Das S, Mitra T, Kapse P, Gosavi SW and Kundu GC: Modulation of the
tumor microenvironment and mechanism of immunotherapy-based drug
resistance in breast cancer. Mol Cancer. 23:922024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zou J, Mai C, Lin Z, Zhou J and Lai G:
Targeting metabolism of breast cancer and its implications in T
cell immunotherapy. Front Immunol. 15:13819702024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kaufman B, Abu-Ahmad M, Radinsky O, Gharra
E, Manko T, Bhattacharya B, Gologan D, Erlichman N, Meshel T, Nuta
Y, et al: N-glycosylation of PD-L1 modulates the efficacy of immune
checkpoint blockades targeting PD-L1 and PD-1. Mol Cancer.
24:1402025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liang D, Liu L, Zhao Y, Luo Z, He Y, Li Y,
Tang S, Tang J and Chen N: Targeting extracellular matrix through
phytochemicals: A promising approach of multi-step actions on the
treatment and prevention of cancer. Front Pharmacol.
14:11867122023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bhavnagari H, Raval A and Shah F:
Deciphering potential role of Hippo signaling pathway in breast
cancer: A comprehensive review. Curr Pharm Des. 29:3505–3518. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang C, Xu S, Yin C, Hu S and Liu P: The
role of the mTOR pathway in breast cancer stem cells (BCSCs):
Mechanisms and therapeutic potentials. Stem Cell Res Ther.
16:1562025. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sakunrangsit N and Ketchart W: Plumbagin
inhibits cancer stem-like cells, angiogenesis and suppresses cell
proliferation and invasion by targeting Wnt/β-catenin pathway in
endocrine resistant breast cancer. Pharmacol Res. 150:1045172019.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ham A, Cho MH, Won HS, Jo J and Lee KE:
β-catenin blockers enhance the effect of CDK4/6 inhibitors on
stemness and proliferation suppression in endocrine-resistant
breast cancer cells. Oncol Rep. 48:1302022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Luo F, Zhang M, Sun B, Xu C, Yang Y, Zhang
Y, Li S, Chen G, Chen C, Li Y and Feng H: LINC00115 promotes
chemoresistant breast cancer stem-like cell stemness and metastasis
through SETDB1/PLK3/HIF1α signaling. Mol Cancer. 23:602024.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu Y, Sun X, Wei C, Guo S, Song C, Zhang
J and Bai J: Targeted drug nanodelivery and immunotherapy for
combating tumor resistance. Comb Chem High Throughput Screen.
28:561–581. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang Z, Li T, Li Y, Wang XI, Liu H, Shen
X, Xu A, Xia T and Xu BO: Cancer stem cell specificity as new
targets in breast tumor treatment. Oncol Res. 33:811–819. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang N, Ma T and Yu B: Targeting
epigenetic regulators to overcome drug resistance in cancers.
Signal Transduct Target Ther. 8:692023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Torabian P, Yousefi H, Fallah A, Moradi Z,
Naderi T, Delavar MR, Ertas YN, Zarrabi A and Aref AR: Cancer stem
cell-mediated drug resistance: A comprehensive gene expression
profile analysis in breast cancer. Pathol Res Pract.
246:1544822023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dimitrakopoulos FI, Kottorou A and Tzezou
A: Endocrine resistance and epigenetic reprogramming in estrogen
receptor positive breast cancer. Cancer Lett. 517:55–65. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Buocikova V, Longhin EM, Pilalis E,
Mastrokalou C, Miklikova S, Cihova M, Poturnayova A, Mackova K,
Babelova A, Trnkova L, et al: Decitabine potentiates efficacy of
doxorubicin in a preclinical trastuzumab-resistant HER2-positive
breast cancer models. Biomed Pharmacother. 147:1126622022.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhu Y, Xia T, Chen DQ, Xiong X, Shi L, Zuo
Y, Xiao H and Liu L: Promising role of protein arginine
methyltransferases in overcoming anti-cancer drug resistance. Drug
Resist Updat. 72:1010162024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Qu L, Liu SJ, Zhang L, Liu JF, Zhou YJ,
Zeng PH, Jing QC and Yin WJ: The role of m6A-mediated DNA damage
repair in tumor development and chemoradiotherapy resistance.
Cancer Control. 31:107327482412471702024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tavares NT, Gumauskaite S, Lobo J,
Jerónimo C and Henrique R: DNA methylation biomarkers for
prediction of response to platinum-based chemotherapy: Where do we
stand? Cancers (Basel). 14:29182022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gemma C, Lai CF, Singh AK, Belfiore A,
Portman N, Milioli HZ, Periyasamy M, Raafat S, Nicholls AJ, Davies
CM, et al: Induction of the TEAD coactivator VGLL1 by estrogen
receptor-targeted therapy drives resistance in breast cancer.
Cancer Res. 84:4283–4297. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Vijayaraghavalu S and Labhasetwar V:
Nanogel-mediated delivery of a cocktail of epigenetic drugs plus
doxorubicin overcomes drug resistance in breast cancer cells. Drug
Deliv Transl Res. 8:1289–1299. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang W, Li M, Ponnusamy S, Chi Y, Xue J,
Fahmy B, Fan M, Miranda-Carboni GA, Narayanan R, Wu J and Wu ZH:
ABL1-dependent OTULIN phosphorylation promotes genotoxic
Wnt/β-catenin activation to enhance drug resistance in breast
cancers. Nat Commun. 11:39652020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kang Y: Landscape of NcRNAs involved in
drug resistance of breast cancer. Clin Transl Oncol. 25:1869–1892.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Shaikh M and Doshi G: Unraveling
non-coding RNAs in breast cancer: Mechanistic insights and
therapeutic potential. Med Oncol. 42:372024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Moradi F, Mohajerani F and Sadeghizadeh M:
CCAT2 knockdown inhibits cell growth, and migration and promotes
apoptosis through regulating the hsa-mir-145-5p/AKT3/mTOR axis in
tamoxifen-resistant MCF7 cells. Life Sci. 311:1211832022.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Raju GSR, Pavitra E, Bandaru SS,
Varaprasad GL, Nagaraju GP, Malla RR, Huh YS and Han YK: HOTAIR: A
potential metastatic, drug-resistant and prognostic regulator of
breast cancer. Mol Cancer. 22:652023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ying Z, Wenjing S, Jing B, Songbin F and
Kexian D: Advances in long non-coding RNA regulating drug
resistance of cancer. Gene. 887:1477262023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yang S and Li D: The role of circRNA in
breast cancer drug resistance. PeerJ. 12:e187332024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yan Y and Zhang J: Mechanisms of tamoxifen
resistance: Insight from long non-coding RNAs. Front Oncol.
14:14585882024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Uppaluri KR, Challa HJ, Gaur A, Jain R,
Krishna Vardhani K, Geddam A, Natya K, Aswini K, Palasamudram K and
K SM: Unlocking the potential of non-coding RNAs in cancer research
and therapy. Transl Oncol. 35:1017302023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Tang H, Chen J, Jiang K, He J, Tang F, Li
D and Wu Y: Unraveling the resistance: Challenges and advances in
PARP inhibitor therapy for BRCA1/2 breast cancer. Anticancer Agents
Med Chem. 26:268–277. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang C, Han X, Kong S, Zhang S, Ning H and
Wu F: Deciphering the mechanisms of PARP inhibitor resistance in
prostate cancer: Implications for precision medicine. Biomed
Pharmacother. 185:1179552025. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wiegmans AP, Ward A, Ivanova E, Duijf PHG,
Adams MN, Najib IM, Van Oosterhout R, Sadowski MC, Kelly G,
Morrical SW, et al: Genome instability and pressure on
non-homologous end joining drives chemotherapy resistance via a DNA
repair crisis switch in triple negative breast cancer. NAR Cancer.
3:zcab0222021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sun Y, Patterson-Fortin J, Han S, Li Z,
Nowicka Z, Hirohashi Y, Kilgas S, Yi JK, Spektor A, Fendler W, et
al: 53BP1 loss elicits cGAS-STING-dependent antitumor immunity in
ovarian and pancreatic cancer. Nat Commun. 15:66762024. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ma L, Chen W, Yang M, Ha S, Xiong S, Zhu
J, Xiang H and Luo G: Discovery and proof of concept of potent dual
Polθ/PARP inhibitors for efficient treatment of homologous
recombination-deficient tumors. J Med Chem. 67:3606–3625. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Guacci A, Cordella A, Rocco T, Giurato G,
Nassa G, Rizzo F, Carlomagno C, Pepe S, Tarallo R and Weisz A:
Identification of a novel truncating mutation in PALB2 gene by a
multigene sequencing panel for mutational screening of breast
cancer risk-associated and related genes. J Clin Lab Anal.
32:e224182018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Foo TK, Tischkowitz M, Simhadri S, Boshari
T, Zayed N, Burke KA, Berman SH, Blecua P, Riaz N, Huo Y, et al:
Compromised BRCA1-PALB2 interaction is associated with breast
cancer risk. Oncogene. 36:4161–4170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Foo TK and Xia B: BRCA1-dependent and
independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage
response and cancer. Cancer Res. 82:3191–3197. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Dilmac S and Ozpolat B: Mechanisms of
PARP-inhibitor-resistance in BRCA-mutated breast cancer and new
therapeutic approaches. Cancers (Basel). 15:36422023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kefala Stavridi A, Appleby R, Liang S,
Blundell TL and Chaplin AK: Druggable binding sites in the
multicomponent assemblies that characterise DNA double-strand-break
repair through non-homologous end joining. Essays Biochem.
64:791–806. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Brouwer I, Sitters G, Candelli A, Heerema
SJ, Heller I, de Melo AJ, Zhang H, Normanno D, Modesti M, Peterman
EJ and Wuite GJ: Sliding sleeves of XRCC4-XLF bridge DNA and
connect fragments of broken DNA. Nature. 535:566–569. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Yang K, Guo R and Xu D: Non-homologous end
joining: Advances and frontiers. Acta Biochim Biophys Sin
(Shanghai). 48:632–640. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Dong W, Zhang H, Zhuang Z and Jiang Y:
PIPKIγ promotes non-homologous end joining through LIG4 to enhance
radiotherapy resistance in triple-negative breast cancer. Cell
Death Dis. 16:5782025. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Du J, Chen F, Yu J, Jiang L and Zhou M:
The PI3K/mTOR inhibitor ompalisib suppresses nonhomologous end
joining and sensitizes cancer cells to radio- and chemotherapy. Mol
Cancer Res. 19:1889–1899. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Caracciolo D, Riillo C, Di Martino MT,
Tagliaferri P and Tassone P: Alternative non-homologous
end-joining: Error-prone DNA repair as cancer's achilles' heel.
Cancers (Basel). 13:13922021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Elsakrmy N, Zhang-Akiyama QM and Ramotar
D: The base excision repair pathway in the nematode caenorhabditis
elegans. Front Cell Dev Biol. 8:5988602020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Antoniali G, Malfatti MC and Tell G:
Unveiling the non-repair face of the Base excision repair pathway
in RNA processing: A missing link between DNA repair and gene
expression? DNA Repair (Amst). 56:65–74. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Madders ECET and Parsons JL: Base excision
repair in chromatin and the requirement for chromatin remodelling.
Adv Exp Med Biol. 1241:59–75. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Caffrey PJ and Delaney S: Chromatin and
other obstacles to base excision repair: Potential roles in
carcinogenesis. Mutagenesis. 35:39–50. 2020.PubMed/NCBI
|
|
82
|
Xin X, Wen T, Gong LB, Deng MM, Hou KZ, Xu
L, Shi S, Qu XJ, Liu YP, Che XF and Teng YE: Inhibition of FEN1
increases arsenic trioxide-induced ROS accumulation and cell death:
Novel therapeutic potential for triple negative breast cancer.
Front Oncol. 10:4252020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chen HW, Kuo WH, Lu YS, Chen IC, Hu FC,
Wang MY, Zahid M, Rogan EG, Cheng AL and Lin CH: Interaction of
base excision repair gene polymorphism and estrogen-DNA adducts in
breast cancer risk among East Asian women. Breast Cancer Res Treat.
208:283–292. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Li F, Sun H, Ren J, Zhang B, Hu X, Fang C,
Lee J, Gu H and Ling D: A nuclease-mimetic platinum nanozyme
induces concurrent DNA platination and oxidative cleavage to
overcome cancer drug resistance. Nat Commun. 13:73612022.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Borszéková Pulzová L, Ward TA and Chovanec
M: XPA: DNA repair protein of significant clinical importance. Int
J Mol Sci. 21:21822020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Szatkowska M and Zdrada-Nowak J: Genetic
polymorphisms in base excision repair (BER) and nucleotide excision
repair (NER) pathways as potential biomarkers for gynecological
cancers: A comprehensive literature review. Cancers (Basel).
17:21702025. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Rajkumar-Calkins AS, Szalat R, Dreze M,
Khan I, Frazier Z, Reznichenkov E, Schnorenberg MR, Tsai YF, Nguyen
H, Kochupurakkal B, et al: Functional profiling of nucleotide
excision repair in breast cancer. DNA Repair (Amst). 82:1026972019.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Manandhar M, Boulware KS and Wood RD: The
ERCC1 and ERCC4 (XPF) genes and gene products. Gene. 569:153–161.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Pietrasik S, Zajac G, Morawiec J,
Soszynski M, Fila M and Blasiak J: Interplay between BRCA1 and
GADD45A and its potential for nucleotide excision repair in breast
cancer pathogenesis. Int J Mol Sci. 21:8702020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Sun L, Fan G, Zhang Z, Chang D, Zhang X,
Zhang T, Geng J, Zhang X, Lin M, Hu C, et al: Phosphorylation of
SIRT7 by ATM causes DNA mismatch repair downregulation and adaptive
mutability during chemotherapy. Cell Rep. 44:1152692025. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Eso Y, Shimizu T, Takeda H, Takai A and
Marusawa H: Microsatellite instability and immune checkpoint
inhibitors: Toward precision medicine against gastrointestinal and
hepatobiliary cancers. J Gastroenterol. 55:15–26. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Ponnusamy L, Mahalingaiah PKS, Chang YW
and Singh KP: Reversal of epigenetic aberrations associated with
the acquisition of doxorubicin resistance restores drug sensitivity
in breast cancer cells. Eur J Pharm Sci. 123:56–69. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Dasgupta H, Islam S, Alam N, Roy A,
Roychoudhury S and Panda CK: Hypomethylation of mismatch repair
genes MLH1 and MSH2 is associated with chemotolerance of breast
carcinoma: Clinical significance. J Surg Oncol. 119:88–100. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Haricharan S, Punturi N, Singh P, Holloway
KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, et al:
Loss of MutL disrupts CHK2-dependent cell-cycle control through
CDK4/6 to promote intrinsic endocrine therapy resistance in primary
breast cancer. Cancer Discov. 7:1168–1183. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Incorvaia L, Bazan Russo TD, Gristina V,
Perez A, Brando C, Mujacic C, Di Giovanni E, Bono M, Contino S,
Ferrante Bannera C, et al: The intersection of homologous
recombination (HR) and mismatch repair (MMR) pathways in DNA
repair-defective tumors. NPJ Precis Oncol. 8:1902024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Niu Z, He J, Wang S, Xue B, Zhang H, Hou
R, Xu Z, Sun J, He F and Pei X: Targeting glycolysis for treatment
of breast cancer resistance: Current progress and future prospects.
Int J Biol Sci. 21:2589–2605. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lu C, Qiao P, Sun Y, Ren C and Yu Z:
Positive regulation of PFKFB3 by PIM2 promotes glycolysis and
paclitaxel resistance in breast cancer. Clin Transl Med.
11:e4002021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Jiang CF, Xie YX, Qian YC, Wang M, Liu LZ,
Shu YQ, Bai XM and Jiang BH: TBX15/miR-152/KIF2C pathway regulates
breast cancer doxorubicin resistance via promoting PKM2
ubiquitination. Cancer Cell Int. 21:5422021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Lin J, Fang W, Xiang Z, Wang Q, Cheng H,
Chen S, Fang J, Liu J, Wang Q, Lu Z and Ma L: Glycolytic enzyme HK2
promotes PD-L1 expression and breast cancer cell immune evasion.
Front Immunol. 14:11899532023. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Paul S, Ghosh S and Kumar S: Tumor
glycolysis, an essential sweet tooth of tumor cells. Semin Cancer
Biol. 86:1216–1230. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Fu W, Sun A and Dai H: Lipid metabolism
involved in progression and drug resistance of breast cancer. Genes
Dis. 12:1013762024. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Bian X, Liu R, Meng Y, Xing D, Xu D and Lu
Z: Lipid metabolism and cancer. J Exp Med. 218:e202016062021.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Liang LC, Zhao L, Yu B, Hu HX, He XH and
Zhang YM: Caffeic acid phenethyl ester reverses doxorubicin
resistance in breast cancer cells via lipid metabolism regulation
at least partly by suppressing the Akt/mTOR/SREBP1 pathway.
Kaohsiung J Med Sci. 39:605–615. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Li J, Guo Y, Zhang W, Xia M, Liu G, Sun Y,
Liu C and Zhong J: Cholesterol metabolism: A strategy for
overcoming drug resistance in tumors. Biochem Pharmacol.
238:1169742025. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Hwang S, Park S, Kim JH, Bang SB, Kim HJ,
Ka NL, Ko Y, Kim SS, Lim GY, Lee S, et al: Targeting HMG-CoA
synthase 2 suppresses tamoxifen-resistant breast cancer growth by
augmenting mitochondrial oxidative stress-mediated cell death. Life
Sci. 328:1218272023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Vishwa R, BharathwajChetty B, Girisa S,
Aswani BS, Alqahtani MS, Abbas M, Hegde M and Kunnumakkara AB:
Lipid metabolism and its implications in tumor cell plasticity and
drug resistance: What we learned thus far? Cancer Metastasis Rev.
43:293–319. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wan M, Pan S, Shan B, Diao H, Jin H, Wang
Z, Wang W, Han S, Liu W, He J, et al: Lipid metabolic reprograming:
The unsung hero in breast cancer progression and tumor
microenvironment. Mol Cancer. 24:612025. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Huang X, Liu B and Shen S: Lipid
metabolism in breast cancer: From basic research to clinical
application. Cancers (Basel). 17:6502025. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Liu Y, Zong X, Altea-Manzano P and Fu J:
Amino acid metabolism in breast cancer: Pathogenic drivers and
therapeutic opportunities. Protein Cell. 16:506–531. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Yu C, Wang N, Chen X, Jiang Y, Luan Y, Qin
W and He W: A photodynamic-mediated glutamine metabolic
intervention nanodrug for triple negative breast cancer therapy.
Mater Today Bio. 19:1005772023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Choi H, Gupta M, Sengupta A, Furth EE,
Hensley C, Weljie AM, Lee H, Lu YT, Pantel A, Mankoff D and Zhou R:
Disruption of redox balance in glutaminolytic triple negative
breast cancer by inhibition of glutaminase and glutamate export.
Neoplasia. 61:1011362025. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Yang L, Chu Z, Liu M, Zou Q, Li J, Liu Q,
Wang Y, Wang T, Xiang J and Wang B: Amino acid metabolism in immune
cells: Essential regulators of the effector functions, and
promising opportunities to enhance cancer immunotherapy. J Hematol
Oncol. 16:592023. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Yoo HC and Han JM: Amino acid metabolism
in cancer drug resistance. Cells. 11:1402022. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Shi DD, Savani MR, Abdullah KG and
McBrayer SK: Emerging roles of nucleotide metabolism in cancer.
Trends Cancer. 9:624–635. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Lv Y, Wang X, Li X, Xu G, Bai Y, Wu J,
Piao Y, Shi Y, Xiang R and Wang L: Nucleotide de novo synthesis
increases breast cancer stemness and metastasis via cGMP-PKG-MAPK
signaling pathway. PLoS Biol. 18:e30008722020. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Hany D, Vafeiadou V and Picard D:
CRISPR-Cas9 screen reveals a role of purine synthesis for estrogen
receptor α activity and tamoxifen resistance of breast cancer
cells. Sci Adv. 9:eadd36852023. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Suleiman H, Emerson A, Wilson PM, Mulligan
KA, Ladner RD and LaBonte MJ: Harnessing nucleotide metabolism and
immunity in cancer: A tumour microenvironment perspective. FEBS J.
292:2155–2172. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Madsen HB, Peeters MJ, Straten PT and
Desler C: Nucleotide metabolism in the regulation of tumor
microenvironment and immune cell function. Curr Opin Biotechnol.
84:1030082023. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Viswanathan S, Parida S, Lingipilli BT,
Krishnan R, Podipireddy DR and Muniraj N: Role of gut microbiota in
breast cancer and drug resistance. Pathogens. 12:4682023.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Ma W, Zhang L, Chen W, Chang Z, Tu J, Qin
Y, Yao Y, Dong M, Ding J, Li S, et al: Microbiota enterotoxigenic
Bacteroides fragilis-secreted BFT-1 promotes breast cancer
cell stemness and chemoresistance through its functional receptor
NOD1. Protein Cell. 15:419–440. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Fu A, Yao B, Dong T, Chen Y, Yao J, Liu Y,
Li H, Bai H, Liu X, Zhang Y, et al: Tumor-resident intracellular
microbiota promotes metastatic colonization in breast cancer. Cell.
185:1356–1372.e26. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Wu H, Liu J, Zhang XH, Jin S, Li P, Liu H,
Zhao L, Wang J, Zhao S, Tian HD, et al: The combination of flaxseed
lignans and PD-1/PD-L1 inhibitor inhibits breast cancer growth via
modulating gut microbiome and host immunity. Drug Resist Updat.
80:1012222025. View Article : Google Scholar : PubMed/NCBI
|
